(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you:

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand-new127 page reportyou will receive70 charts- all unavailable elsewhere.

The127-page report provides clear detailed insight into the gene therapy market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope:

Gene Therapy market forecastsfrom2017-2027

This reportassesses the approved gene therapy productsin the market and givesrevenue to 2027 for Neovasculgen

Providesqualitative analysis and forecastof thesubmarket by indicationfor the period 2017-2027: Cancer Cardiovascular disorders Rare diseases Ophthalmological diseases Other therapeutic uses

Profilesleading companiesthat will be important in the development of the gene therapy market. For each company, developments and outlooks are discussed and companies covered in this chapter include: UniQure Biogen Bluebird Bio Spark Therapeutics Applied Genetics Technologies Corporation Oxford Biomedica GenSight Biologics

Assesses the outlook for theleading gene treatment R&D pipelinefor 2016 and discusses technological progress and potential. Profiles appear for gene therapy drug candidates, withrevenue forecasts for six leading agents: SPK-RPE65 (Spark Therapeutics) Collategene (AMG0001, AnGes MG/Vical) Invossa (TissueGene-C, TissueGene Inc/Kolon Life Science) BC-819 (BioCancell) Lenti-D (Bluebird Bio) GSK2696273 (GlaxoSmithKline)

Provides qualitative analysis of trends that will affect the gene therapies market, from the perspective of pharmaceutical companies, during the period 2017 to 2027.SWOT analysisis provided andan overview of regulation of the gene therapy market by leading regiongiven.

Our study discussesfactors that influence the marketincluding these: Translation of research into marketable products modifying human DNA - gene transfer for therapeutic use, altering the nuclear genome Genomic editing technology and other supporting components Collaborations to develop and launch gene-based products - acquisitions and licensing deals Supporting technologies for human genetic modification, gene replacement and targeted drug delivery Gene therapies for ophthalmologic diseases - next-generation medicines Regulations in the United States, the European Union and Japan - overcoming technological and medical challenges to pass clinical trials.

Visiongain's study is intended for anyone requiring commercial analyses for the gene therapy market. You find data, trends and predictions.

Buy our report todayGene Therapy R&D and Revenue Forecasts 2017-2027: Cancer, Cardiovascular, Rare Diseases, Ophthalmologic, Other Diseases.

To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100

Or click on https://www.visiongain.com/Report/1954/Gene-Therapy-R-D-and-Revenue-Forecasts-2017-2027

List of Companies and Organisations Mentioned in the Report:

Active Medical, Inc.

AngioDynamics, Inc.

Aspen Laboratories

AtriCure, Inc.

Barcapel Foundation

Biosense Webster, Inc.

Boston Scientific Corporation

British Association of Aesthetic Plastic Surgeons (BAAPS)

BSD Medical Corporation

C.R. Bard

Cosman medical, Inc.

Covidien

DFINE, Inc.

Endosense SA

Ethicon

Food and Drug Administration (FDA)

Galil medical, Inc.

Johnson & Johnson

Linvatec Canada ULC

Macmillan Cancer Support

Medtronic

Microsulis Medical Ltd.

Monteris Medical

National Institute of Health Research (NIHR)

nContact, Inc.

NeuroTherm, Inc.

NeuWave Medical, Inc.

NxThera, Inc.

Olympus Corporation

Perseon Corporation

Profound Medical Corp.

Royal Brompton & Harefield NHS Foundation Trust

Royal Philips

Shandong Provincial Hospital

Smith & Nephew

SonaCare Medical

St Jude Medical

Terumo Europe

The American Heart Association

Trod Medical N.V.

University College London

To see a report overview please email Sara Peerun on sara.peerun@visiongain.com

SOURCE Visiongain Ltd

See the rest here:

Gene Therapy R&D and Revenue Forecasts 2017-2027 - PR Newswire (press release)